Shifting Treatment Paradigms in R/R ALL

Author(s):

Kristen M. O’Dwyer, MD ,Aaron Logan, MD, PhD

Panelists discuss how minimal residual disease (MRD) outcomes with obecabtagene autoleucel (obe-cel) compare with those with brexucabtagene autoleucel (brexu-cel) and how the FDA approval of obe-cel may impact treatment decisions in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), including considerations for patient factors, such as MRD status, Philadelphia status, and high-risk features.

EP: 1.Introduction to CAR T-Cell Therapies in R/R ALL

EP: 2.Clinical Trials and Real-World Data on Brexu-Cel

EP: 3.Obe-Cel and MRD Outcomes: Insights and Comparisons

Now Viewing

EP: 4.Shifting Treatment Paradigms in R/R ALL

EP: 5.Optimizing Bridging Therapies and Post–CAR T Approaches

EP: 6.Addressing Toxicities in CAR T-Cell Therapy

EP: 7.Health Care Resource Utilization and Transition of Care

EP: 8.Outpatient CAR T Therapy and Expanding Access

EP: 9.Reflections and Future Directions in R/R ALL

Video content above is prompted by the following:

Dr. O’Dwyer to Dr. Shaughnessy: What are your impressions of the MRD outcomes with obe-cel compared with MRD outcomes reported with brexu-cel so far?
Resource links: Valtis YK et al. MRD negativity D28 after brexu-cel. ASH 2024 abstract, or see Appendix 5.
Dr. O’Dwyer to Dr. Logan [then open to panelists]: How does the FDA approval of obe-cel change your treatment landscape and decisions for R/R ALL?
Are there specific patients with R/R ALL for whom you would more likely consider brexu-cel vs obe-cel [eg, Philadelphia status, MRD status, high-risk features, extramedullary disease, age, performance score]?
Does the FDA approval without a Risk Evaluation Mitigation Strategy program influence your treatment approach?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!